Perspective, Therapeutics announced that the first patient was dosed in a new cohort of a Phase 1/2a trial evaluating the safety of 212PbVMT01, ...

Perspective Therapeutics, Inc.’s CATX share price has dipped by 7.63%, which has investors questioning if this is right time ...